The Latest Breaking News from MEI Pharma

With growing medical needs globally, R&D initiatives, and rapid adoption of emerging technologies like genAI, the pharma industry is well-poised to experience robust expansion. Thus, investors could consider buying top pharma stocks MEI Pharma (MEIP), Hypera (HYPMY), Aurinia Pharmaceuticals (AUPH), and Bayer (BAYRY) this month. Read on.

According to Benzinga Pro data, during Q3, MEI Pharma (NASDAQ:MEIP) posted sales of $9.69 million. Earnings were up 28.22%, but MEI Pharma still reported an overall loss of $8.72 million.

Upgrades For Aris Water Solutions Inc (NYSE:ARIS), Capital One upgraded the previous rating of Equal-Weight to Overweight. The stock has a 52-week-high of $19.16 and a 52-week-low of $10.06. At the end of the last trading period, Aris Water Solutions closed at $18.55.

Here's a roundup of top developments in the biotech space over the last 24 hours.

Jefferies cut the price target on MEI Pharma, Inc. (NASDAQ: MEIP) from $4 to $1. MEI Pharma shares fell 44.2% to $1.01 in pre-market trading.

Gainers

MEI Pharma Inc (NASDAQ: MEIP) shares are plunging in Thursday's after-hours session after the company provided an investor update following a recent meeting with the U.S. Food and Drug Administration.

According to data from Benzinga Pro, during Q2, MEI Pharma's (NASDAQ:MEIP) reported sales totaled $18.22 million. Despite a 51.46% increase in earnings, the company posted a loss of $5.77 million.

MEI Pharma (NASDAQ:MEIP) reported its Q2 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings MEI Pharma beat estimated earnings by 55.0%, reporting an EPS of $-0.09 versus an estimate of $-0.2.